In a groundbreaking study conducted by researchers at the Johns Hopkins Bloomberg School of Public Health in the United States, human volunteers were safely and effectively infected with the Zika virus for the first time. This controlled human infection model, which was previously deemed controversial due to the risks involved and the lack of treatments for Zika, has received approval from U.S. regulators and the World Health Organization (WHO) as a safe and scientifically significant approach.
Zika is a viral infection predominantly transmitted by mosquitoes. While it generally causes mild or no symptoms, a major outbreak in the Americas in 2015 and 2016 revealed its potential dangers to pregnant women and their unborn children, leading to devastating birth defects such as microcephaly, a condition characterized by a notably small head and brain. Despite its severity, there are currently no available vaccines or treatments for Zika, and the outbreak ended before potential solutions could be fully tested. Although reported infections decreased worldwide, the WHO has warned that surveillance of Zika can be unreliable, transmission patterns are not well understood, and the virus is already established in 91 countries, with climate change likely to further facilitate its spread.
Dr. Anna Durbin, the lead researcher at Johns Hopkins, emphasizes the necessity of developing countermeasures against Zika as infections could resurge at any time. She also highlights the mental health burden faced by pregnant women in affected regions, who bear the constant worry about the virus and its potential effects on their babies, as well as the limited protection options available to them.
To conduct the study, Durbin and her team exposed 20 female volunteers who were not pregnant or lactating to two strains of Zika. All of the participants developed confirmed infections, albeit with only mild symptoms. An additional eight volunteers were given a placebo. In order to mitigate any risks, the patients were kept under close observation in a monitored inpatient unit until they tested negative for the virus. Moreover, they agreed to use contraception for a period of two months following the infection.
The next stage of the research aims to evaluate the impact of the Zika strains on male volunteers, particularly to determine the duration of infectivity in semen since the virus can also be transmitted sexually. Durbin reveals that several vaccine manufacturers have already shown interest in using these strains to test their experimental products.
The findings of the study were presented as an abstract at the annual meeting of the American Society of Tropical Medicine and Hygiene held in Chicago. This successful experiment marks a significant step forward in understanding Zika and developing effective vaccines and treatments to combat its potential resurgence in the future.